The clinical value of large neuroimaging data sets in Alzheimer's disease.

Rapid advances in neuroimaging and cyberinfrastructure technologies have brought explosive growth in the Web-based warehousing, availability, and accessibility of imaging data on a variety of neurodegenerative and neuropsychiatric disorders and conditions. There has been a prolific development and emergence of complex computational infrastructures that serve as repositories of databases and provide critical functionalities such as sophisticated image analysis algorithm pipelines and powerful three-dimensional visualization and statistical tools. The statistical and operational advantages of collaborative, distributed team science in the form of multisite consortia push this approach in a diverse range of population-based investigations.

[1]  Michael Weiner,et al.  Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjects , 2008, NeuroImage.

[2]  Michael Weiner,et al.  Automated 3d Mapping of Baseline and 12-month Associations between Three Verbal Memory Measures and Hippocampal Atrophy in 490 Adni Subjects and the Alzheimer's Disease Neuroimaging Initiative , 2022 .

[3]  A. Toga,et al.  Tracking Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[4]  Danielle J. Harvey,et al.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes , 2010, Alzheimer's & Dementia.

[5]  G B Frisoni,et al.  The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[6]  C. Jack,et al.  Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort , 2010, Neurobiology of Aging.

[7]  A. Dale,et al.  Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. , 2010, Radiology.

[8]  Anqi Qiu,et al.  Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease , 2009, NeuroImage.

[9]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[10]  Michael W. Weiner,et al.  Obesity is linked with lower brain volume in 700 AD and MCI patients , 2010, Neurobiology of Aging.

[11]  A. Toga,et al.  Multisite neuroimaging trials , 2009, Current opinion in neurology.

[12]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[13]  Prasant Chandran,et al.  Paradigm shift in translational neuroimaging of CNS disorders. , 2011, Biochemical pharmacology.

[14]  G. Frisoni,et al.  Functional network disruption in the degenerative dementias , 2011, The Lancet Neurology.

[15]  Arthur W. Toga,et al.  Effi cient , distributed and interactive neuroimaging data analysis using the LONI Pipeline , 2009 .

[16]  Nick C. Fox,et al.  Biomarkers for Alzheimer's disease therapeutic trials , 2011, Progress in Neurobiology.

[17]  Amity E. Green,et al.  Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, Human brain mapping.

[18]  Norbert Schuff,et al.  Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease , 2010, NeuroImage.

[19]  Paul M. Thompson,et al.  Staging Alzheimer's disease progression with multimodality neuroimaging , 2011, Progress in Neurobiology.

[20]  David Manset,et al.  Virtual imaging laboratories for marker discovery in neurodegenerative diseases , 2011, Nature Reviews Neurology.

[21]  Ronald C Petersen,et al.  Alzheimer's disease: progress in prediction , 2010, The Lancet Neurology.

[22]  A. Dale,et al.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease , 2009, Human brain mapping.

[23]  Olaf Sporns,et al.  THE HUMAN CONNECTOME: A COMPLEX NETWORK , 2011, Schizophrenia Research.

[24]  Arthur W. Toga,et al.  Provenance in neuroimaging , 2008, NeuroImage.

[25]  Amity E. Green,et al.  3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI , 2010, Human brain mapping.

[26]  Arthur W. Toga,et al.  Online resource for validation of brain segmentation methods , 2009, NeuroImage.

[27]  Norbert Schuff,et al.  3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry , 2008, NeuroImage.

[28]  Kiralee M. Hayashi,et al.  Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. , 2007, Archives of neurology.

[29]  Norbert Schuff,et al.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, NeuroImage.

[30]  A. Dale,et al.  Subregional neuroanatomical change as a biomarker for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[31]  M. Weiner,et al.  Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia , 2011, Trends in Neurosciences.

[32]  A. Toga,et al.  Neuroimaging as endpoints in clinical trials: Are we there yet? Perspective from the first Provence workshop , 2011, Molecular Psychiatry.

[33]  Russell A. Poldrack,et al.  Decoding Continuous Variables from Neuroimaging Data: Basic and Clinical Applications , 2011, Front. Neurosci..

[34]  Philip S. Insel,et al.  Nonlinear time course of brain volume loss in cognitively normal and impaired elders , 2012, Neurobiology of Aging.

[35]  Harald Hampel,et al.  Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.

[36]  Michael W. Weiner,et al.  Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans , 2010, Neurobiology of Aging.

[37]  Arthur W. Toga,et al.  The informatics core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[38]  K. Amunts,et al.  Towards multimodal atlases of the human brain , 2006, Nature Reviews Neuroscience.

[39]  D. Stott Parker,et al.  Neuroimaging Study Designs, Computational Analyses and Data Provenance Using the LONI Pipeline , 2010, PloS one.

[40]  A. Dale,et al.  Regional rates of neocortical atrophy from normal aging to early Alzheimer disease , 2009, Neurology.

[41]  A. Evans,et al.  Large-scale morphometric analysis of neuroanatomy and neuropathology , 2005, Anatomy and Embryology.

[42]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[43]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[44]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[45]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[46]  Daoqiang Zhang,et al.  Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.

[47]  C. Jack,et al.  Boosting power for clinical trials using classifiers based on multiple biomarkers , 2010, Neurobiology of Aging.

[48]  Jyrki Lötjönen,et al.  Measurement of hippocampal atrophy using 4D graph-cut segmentation: Application to ADNI , 2010, NeuroImage.

[49]  A. W. Toga,et al.  3D maps localize caudate nucleus atrophy in 400 Alzheimer’s disease, mild cognitive impairment, and healthy elderly subjects , 2010, Neurobiology of Aging.

[50]  Arthur W. Toga,et al.  Neuroinformatics Original Research Article , 2022 .

[51]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[52]  Paul M. Thompson,et al.  Robust Surface Reconstruction via Laplace-Beltrami Eigen-Projection and Boundary Deformation , 2010, IEEE Transactions on Medical Imaging.

[53]  G. Alexander,et al.  Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment , 2010, Journal of Neuroscience Methods.

[54]  Paul M. Thompson,et al.  What is where and why it is important , 2007, NeuroImage.

[55]  Christian Windischberger,et al.  Toward discovery science of human brain function , 2010, Proceedings of the National Academy of Sciences.

[56]  Norbert Schuff,et al.  Alzheimer’s Disease Neuroimaging Initiative: A one-year follow up study using Tensor-Based Morphometry correlating degenerative rates, biomarkers and cognition , 2009 .

[57]  Michael Weiner,et al.  and the Alzheimer’s Disease Neuroimaging Initiative* , 2007 .

[58]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[59]  Eric M Reiman,et al.  The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[60]  A. Dale,et al.  Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. , 2009, Radiology.

[61]  Magda Tsolaki,et al.  AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America , 2011, NeuroImage.